Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

5.220 +0.200 (+3.98%)
Streaming Delayed Price Updated: 12:47 PM EST, Dec 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Candel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference
From Candel Therapeutics
Via GlobeNewswire
Candel Therapeutics Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer
From Candel Therapeutics
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
On Friday, 209 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Meta Platforms (NASDAQ:FB) was the largest firm on a market cap... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2022 ↗
 
Via Benzinga
News headline image
Candel Therapeutics to Host Virtual R&D Day on December 6, 2022
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Upcoming Investor Conference Participation for November
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models
From Candel Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers 
Via Benzinga
News headline image
Looking Into Candel Therapeutics's Recent Short Interest ↗
Candel Therapeutics's (NASDAQ:CADL) short percent of float has risen 15.38% since its last report. The company recently reported that it has 57 thousand shares sold short, which is 0.3% of all regular... 
Via Benzinga
News headline image
Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday ↗
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers Statera BioPharma (NASDAQ:STAB) shares increased by 33.1% to $0.2 during Friday's pre-market session. The company's market cap stands at $10.4 million. 
Via Benzinga
News headline image
Tesla, AT&T, AMD, Nvidia, Candel Therapuetics: What's Happening With These Top 5 Trending Stocks ↗
Major U.S. indices closed in the red on Thursday as investors continued to digest higher Treasury yields as well as key earnings. The yield in the benchmark U.S. 10-year Treasuries topped 4.239%, a... 
Via Benzinga
News headline image
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary ↗
 
Via Benzinga
News headline image
Candel Secures European Medicines Agency Orphan Drug Status For Brain Tumour Candidate ↗
The European Medicines Agency (EMA) Committee for Orphan Medical Products (COMP) has issued a positive opinion on Candel Therapeutics’ (NASDAQ: CADL) application for orphan drug designation for... 
Via Benzinga
News headline image
Looking Into Candel Therapeutics's Return On Capital Employed ↗
Benzinga Pro data, Candel Therapeutics (NASDAQ:CADL) reported Q2 sales of $31 thousand. Earnings fell to a loss of $4.15 million, resulting in a 374.71% decrease from last quarter. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers Aridis Pharmaceuticals (NASDAQ:ARDS) shares moved upwards by 20.1% to $1.79 during Wednesday's after-market session. The market value of their outstanding shares is at $31.6 million. 
Via Benzinga
News headline image
71 Biggest Movers From Yesterday ↗
Gainers Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA granted new drug product exclusivity to Evoke Pharma's Gimoti (... 
Via Benzinga
News headline image
38 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) climbed 329.2% to $10.43 after Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a deal to acquire the company for $... 
Via Benzinga
News headline image
54 Biggest Movers From Yesterday ↗
Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) shares jumped 325.9% to close at $10.35 on Tuesday after Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a deal to... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic Dermatitis Treatment Aces Mid-stage Study But Lack... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 ↗
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: 
Via Benzinga
News headline image
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More ↗
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
News headline image
60 Biggest Movers From Yesterday ↗
Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares surged 308.1% to settle at $9.59 on Tuesday after the company signed an agreement with Waas Group for the... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>